BR112014029233A2 - método para diagnosticar se um indivíduo grávido não está em risco, uso, dispositivo e conjunto - Google Patents

método para diagnosticar se um indivíduo grávido não está em risco, uso, dispositivo e conjunto

Info

Publication number
BR112014029233A2
BR112014029233A2 BR112014029233A BR112014029233A BR112014029233A2 BR 112014029233 A2 BR112014029233 A2 BR 112014029233A2 BR 112014029233 A BR112014029233 A BR 112014029233A BR 112014029233 A BR112014029233 A BR 112014029233A BR 112014029233 A2 BR112014029233 A2 BR 112014029233A2
Authority
BR
Brazil
Prior art keywords
diagnose
risk
pregnant individual
pregnant
individual
Prior art date
Application number
BR112014029233A
Other languages
English (en)
Other versions
BR112014029233A8 (pt
Inventor
Hund Mantin
Schmid Maria
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014029233(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP12183508.6A external-priority patent/EP2706359A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014029233A2 publication Critical patent/BR112014029233A2/pt
Publication of BR112014029233A8 publication Critical patent/BR112014029233A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112014029233A 2012-06-27 2013-06-24 método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio BR112014029233A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173886 2012-06-27
EP12183508.6A EP2706359A1 (en) 2012-09-07 2012-09-07 Means and methods applying sFlt-1/PlGF or Endoglin/PlGF ratio to rule-out onset of preeclampsia within a certain time period
PCT/EP2013/063115 WO2014001244A1 (en) 2012-06-27 2013-06-24 MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

Publications (2)

Publication Number Publication Date
BR112014029233A2 true BR112014029233A2 (pt) 2017-06-27
BR112014029233A8 BR112014029233A8 (pt) 2019-01-29

Family

ID=48741083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029233A BR112014029233A8 (pt) 2012-06-27 2013-06-24 método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio

Country Status (12)

Country Link
US (1) US20150338415A1 (pt)
EP (1) EP2867670B1 (pt)
JP (1) JP5937756B2 (pt)
KR (2) KR101996123B1 (pt)
CN (1) CN104412107B (pt)
BR (1) BR112014029233A8 (pt)
CA (1) CA2871878C (pt)
ES (1) ES2681238T3 (pt)
HK (1) HK1208264A1 (pt)
MX (1) MX356775B (pt)
SG (1) SG11201407667UA (pt)
WO (1) WO2014001244A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2014135488A1 (en) 2013-03-04 2014-09-12 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
CA2936883C (en) * 2014-01-24 2022-06-28 Martin Hund Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
CN106662589B (zh) * 2014-03-21 2019-07-30 艾基诺米公司 先兆子痫的早期检测
JP2015207111A (ja) * 2014-04-18 2015-11-19 ソニー株式会社 検査サーバ、検査方法および検査システム
SI3569697T1 (sl) 2014-06-17 2022-05-31 Asherman Therapy, S.L. Terapija z matičnimi celicami pri patologijah endometrija
EP3423834B1 (en) * 2016-02-29 2022-08-17 Roche Diagnostics GmbH Igfbp-7 as a marker in preeclampsia
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
MX2020002788A (es) 2017-09-13 2020-09-14 Progenity Inc Biomarcadores de preeclampsia y sistemas y metodos relacionados.
WO2020016441A1 (en) * 2018-07-20 2020-01-23 Roche Diagnostics Gmbh Prediction of preeclampsia based on igfbp-7
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN114200137B (zh) * 2020-09-16 2023-09-01 四川大学 一种以商品化磁珠为内标的比率免疫分析方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916606B2 (en) * 1986-04-30 2005-07-12 Bioveris Corporation Electrochemiluminescent assays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US7141436B2 (en) * 1999-11-03 2006-11-28 Science And Technology Corp. Immunoassay and reagents and kits for performing the same
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
OA12890A (en) 2002-07-19 2006-10-13 Beth Israel Hospital Methods of diagnosing and treating pre-eclampsia or eclampsia.
EP1664797B1 (en) * 2003-09-23 2015-11-11 The General Hospital Corporation Screening for preeclampsia
MX2007003522A (es) * 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
ES2475975T3 (es) 2004-12-21 2014-07-11 Yale University Diagnóstico de la preeclampsia
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
DE602007012272D1 (de) * 2006-09-07 2011-03-10 Merck Sharp & Dohme Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
EP2120573A4 (en) * 2007-02-12 2011-05-25 Merck Sharp & Dohme DERIVATIVES OF PIPERIDINE
US20090068683A1 (en) * 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
WO2009089286A1 (en) 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
CN110187121B (zh) 2008-10-31 2022-07-01 耶鲁大学 子痫前期检测和治疗的方法和组合物
WO2010059952A1 (en) * 2008-11-20 2010-05-27 Perkinelmer Health Sciences, Inc. Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
CN102893156A (zh) * 2009-12-21 2013-01-23 爱尔兰国立科克大学 子痫前期风险的检测
CA2793487A1 (en) * 2010-04-13 2011-10-20 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
EP2383579A1 (en) * 2010-12-17 2011-11-02 F. Hoffmann-La Roche AG sFlt-1, cardiac troponins and natriuretic peptides in the recognition of therapy with HER-2 inhibitors
EP2490027A1 (en) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1

Also Published As

Publication number Publication date
SG11201407667UA (en) 2015-02-27
CA2871878C (en) 2021-08-10
JP2015525870A (ja) 2015-09-07
JP5937756B2 (ja) 2016-06-22
KR20160116060A (ko) 2016-10-06
ES2681238T3 (es) 2018-09-12
CA2871878A1 (en) 2014-01-03
EP2867670A1 (en) 2015-05-06
EP2867670B1 (en) 2018-05-30
US20150338415A1 (en) 2015-11-26
KR20150023063A (ko) 2015-03-04
MX356775B (es) 2018-06-13
HK1208264A1 (en) 2016-02-26
MX2014014463A (es) 2015-02-12
BR112014029233A8 (pt) 2019-01-29
CN104412107A (zh) 2015-03-11
KR101996123B1 (ko) 2019-07-03
CN104412107B (zh) 2018-06-08
AU2013283540A8 (en) 2014-11-20
WO2014001244A1 (en) 2014-01-03
AU2013283540A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
BR112014029233A2 (pt) método para diagnosticar se um indivíduo grávido não está em risco, uso, dispositivo e conjunto
DK3017520T3 (da) Solcelleanordning
DK2796709T3 (da) Vindmøllevingeholdeindretning
FI20120340A (fi) Kosketusrajapintalaite ja rakenne
BR302013003551S1 (pt) Configuração aplicada a dispositivo portátil
BR302012006307S1 (pt) Configuração aplicada em dispositivo médico
CO6970576A2 (es) Dispositivo contador para atrapar tapones selectivamente
DK2669508T3 (da) Vingefastholdelsesindretning
DK2617362T3 (da) Prøveudtagnings-, fortyndings- og udtømningsindretning
BR302012005120S1 (pt) Padrao ornamnetal aplicado a interface grafica
FI20120365A (fi) Oveen liitettävä lukkolaite
BR302013005473S1 (pt) Configuração aplicada em dispositivo médico
BR112015023736A2 (pt) método para manufaturar dispositivo fotovoltaico
BR112015017471A2 (pt) dispositivo conversor de corrente alternada para corrente alternada
BR302013006845S1 (pt) Configuração aplicada a dispositivo de diagnóstico
BR112014006581A2 (pt) dispositivo de desenho de aeronave, programa de desenho de aeronave, e método de desenho de aeronave
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
DK2920282T3 (da) Alkylenkoblede phenoler til anvendelse i biodieselmotorer
BR302013000587S1 (pt) Configuração aplicada em dispositivo médico.
BR302012004409S1 (pt) Padrão aplicado a interface gráfica
DK2679978T3 (da) Prøvetestanordning og -fremgangsmåde
PL2953913T5 (pl) Stosowanie suchej zaprawy tynkarskiej o właściwościach definiowanych według specjalnych metod badawczych
FR3013901B1 (fr) Dispositif electrochimique autophotorechargeable
DK2951552T3 (da) Opfangningsanordning til engangsbrug
FI20135799L (fi) Kaivon yhteydessä käytettävä turvalaite

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]